DAIC

FEBRUARY 7, 2024

This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022. Cardiovascular disease is the leading cause of death globally, taking an estimated 695,000 lives in 2021 in the United States, about 1 in every 5 deaths, according to the CDC.

Technology 116

Technology Cardiovascular Disease Best Practices AFIB 116

DAIC

JUNE 28, 2024

Getty Images milla1cf Fri, 06/28/2024 - 08:10 June 27, 2024 — Cardiovascular disease is the leading cause of death for women, and gaps in care and access persist between women and men. Similarly, cardiovascular research and clinical studies often underrepresent women, resulting in subpar treatment outcomes.

Cardiovascular Disease 105

Cardiovascular Disease Obesity Research Heart Disease 105

Science Daily - Heart Disease

JULY 25, 2024

3D-printed blood vessels, which closely mimic the properties of human veins, could transform the treatment of cardiovascular diseases.

Outcomes 121

Outcomes Technology Cardiovascular Disease 121

Cardiometabolic Health Congress

FEBRUARY 1, 2024

Other studies have also unearthed more intricate connections which suggests that physiological conditions, underpinned by biological and chemical factors, may also play a pivotal role in influencing cardiovascular disease (CVD). In 2021 alone, CVD accounted for over 900,000 deaths in the U.S. and approximately 19.91 million globally.

Cardiovascular Disease 105

Cardiovascular Disease Coronary Artery Bypass Graft Heart Disease Risk Factors 105

Circulation

MARCH 19, 2025

The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors.

Cancer 55

Cancer Cardio Oncology Cardiovascular Disease Pediatrics 55

Medical Xpress - Cardiology

DECEMBER 24, 2024

Cardiovascular diseases remain a global health crisis, spurring an urgent demand for innovative diagnostic tools that enable early detection and effective treatment. These cutting-edge advancements promise to enhance patient care and outcomes by providing real-time insights into heart health.

Cardiovascular Disease 88

Cardiovascular Disease Innovation Patient Care Outcomes 88

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

DAIC

JANUARY 18, 2024

Highlights from "Addressing Structural Racism Through Public Policy Advocacy: A Policy Statement from the American Heart Association" include: - During the past few years, the largest increases in cardiovascular disease deaths were among Asian, Black and Hispanic adults in the U.S. is tied to structural discrimination. -

Cardiovascular Disease 109

Cardiovascular Disease Health Disparities Education Public Health 109

Open Heart

FEBRUARY 4, 2025

Our aim was to evaluate whether this extends to predicting cardiovascular mortality after 20 years of follow-up. Cardiovascular mortality was defined as death from coronary heart disease, stroke and other cardiovascular aetiology such as heart failure or peripheral vascular disease. to 1.23).

Outcomes 52

Outcomes Hypertension Heart Failure Cardiovascular Disease 52

Journal of the American Heart Association

FEBRUARY 14, 2024

One such syndrome that has been associated with poor outcomes is cognitive frailty: the simultaneous presence of cognitive impairment, without evidence of dementia, and physical frailty, which results in decreased cognitive reserve.

Cardiovascular Disease 73

Cardiovascular Disease Dementia Obesity Risk Factors 73

European Journal of Heart Failure

MARCH 10, 2025

Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis. Abstract Aims Clonal haematopoiesis (CH) is recognized as a significant risk factor for various non-haematologic conditions, including cardiovascular diseases.

Heart Failure 40

Heart Failure Outcomes Coronary Artery Disease Risk Factors 40

Medical Xpress - Cardiology

FEBRUARY 27, 2025

Hospital-based researchers from Denmark have reported a substantial increase in cardiovascular disease risk among male users of anabolic androgenic steroids (AAS). Long-term health outcomes for AAS users show extreme increases in heart-related health risks.

Cardiovascular Disease 139

Cardiovascular Disease Hospital Research Outcomes 139

Frontiers in Cardiovascular Medicine

FEBRUARY 10, 2025

Despite its known correlations with risk of cardiovascular disease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening.

Cardiovascular Disease 52

Cardiovascular Disease Biomarkers Obesity Outcomes 52

Journal of the American Heart Association

FEBRUARY 13, 2024

BackgroundIn patients with atherosclerotic cardiovascular disease, increasing age is concurrently associated with higher risks of ischemic and bleeding events. ConclusionsAge does not modify the impact of aspirin dosing (81 mg or 325 mg daily) on clinical end points in secondary prevention of atherosclerotic cardiovascular disease.

Cardiovascular Disease 74

Cardiovascular Disease Myocardial Infarction Hospital Stroke 74

Medical Xpress - Cardiology

JULY 15, 2024

Dialysis patients using a more traditional home hemodialysis procedure have lower incidence of cardiovascular disease than patients using a less invasive peritoneal catheter for dialysis at home, according to a study led by a University of Cincinnati College of Medicine researcher.

Cardiovascular Disease 105

Cardiovascular Disease Outcomes Research 105

DAIC

MARCH 26, 2024

milla1cf Tue, 03/26/2024 - 13:00 March 26, 2024 — Esperion announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen ) Outcomes subgroup analyses as poster presentations at th e 2024 American College of Cardiology’s Annual Scientific Session ( ACC.24 24 ) in Atlanta, Georgia.

Outcomes 105

Outcomes Obesity Cardiovascular Disease Atherosclerosis 105

Cardiometabolic Health Congress

JANUARY 15, 2025

Atherosclerosisa key driver of cardiovascular disease (CVD)continues to be a significant global health issue. Studies cited in the 2024 Journal of the American College of Cardiology (JACC) show that SMuRFless MI patients have worse short-term outcomes compared to those with traditional risk factors.

Atherosclerosis 59

Atherosclerosis Plaque Myocardial Infarction Risk Factors 59

Dr. Paddy Barrett

NOVEMBER 29, 2024

We need to do better if we want to majorly impact rates of cardiovascular disease worldwide. Those in the lower blood pressure group will postpone the onset of cardiovascular disease by over 5 years and extend their lifespan by over 4 years. Outcome over process, in my view, works best here. There are others also.

Blood Pressure 87

Blood Pressure ACE Inhibitor Hypertension Cardiovascular Disease 87

Heart BMJ

FEBRUARY 26, 2025

One in five women suffer from hypertension worldwide, and almost half of the mortality in women is caused by cardiovascular disease (CVD) (WHO). The timely launch of the Women’s Health Strategy for England in 2022 focuses attention on the changing health and needs of women across their life.

Hypertension 59

Hypertension Cardiovascular Disease Outcomes 59

Hypertension Journal

DECEMBER 5, 2024

Recent consensus statements combine an increase in blood pressure upon standing with standing hypertension, but whether these 2 components have similar risk associations with cardiovascular disease (CVD) is unknown.METHODS:The ARIC study (Atherosclerosis Risk in Communities) measured supine and standing blood pressure during visit 1 (19871989).

Cardiovascular Disease 60

Cardiovascular Disease Hypertension Blood Pressure Heart Disease 60

Cardiometabolic Health Congress

JANUARY 16, 2025

Atherosclerosis (ASVD) remains a leading driver of cardiovascular disease (CVD), a global health challenge that claims millions of lives each year. Precision Medicine: Personalizing Prevention for Better Outcomes Precision medicine provides tools to customize prevention and treatment plans based on individual risk factors.

Atherosclerosis 59

Atherosclerosis Risk Factors Coronary Artery Disease Cardiovascular Disease 59

Frontiers in Cardiovascular Medicine

JANUARY 22, 2024

Introduction Cardiovascular diseases (CVDs) are the most important cause of premature death and disability worldwide. The etiological risk factors of CVDs are widely known and include dyslipidemia, obesity, diabetes, and chronic cigarette consumption. Results Eight reviews, including a total of 153 studies, were identified.

Cardiovascular Disease 64

Cardiovascular Disease Risk Factors Physiology Obesity 64

The New England Journal of Medicine

MARCH 28, 2025

Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.

Diabetes 75

Diabetes Kidney Disease Cardiovascular Disease Outcomes 75

Cardiovascular Diabetology

JULY 17, 2024

The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-ca.

Diabetes 105

Diabetes Cardiovascular Disease Outcomes Research 105

Frontiers in Cardiovascular Medicine

JUNE 25, 2024

Among the leading causes of natural death are cardiovascular diseases, cancer, and respiratory diseases. Inconclusive clinical outcomes of vitamin D supplements in cardiovascular diseases demonstrate the need to identify cause-effect relationships without bias.

Cardiovascular Disease 52

Cardiovascular Disease Genetic predisposition Pharmacology Cancer 52

Heart BMJ

JUNE 25, 2024

Background We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovascular diseases in a typical rural setting. We found substantial reduction in risk of primary outcome both in relative and absolute scales (HR 0.50, 95% CI 0.38 to 5.3%).

Cardiovascular Disease 59

Cardiovascular Disease Myocardial Infarction Pharmacology Angina 59

Frontiers in Cardiovascular Medicine

NOVEMBER 19, 2024

Global progress in addressing cardiovascular diseases (CVD) has been insufficient to attain the nine WHO non-communicable disease (NCD) targets and the Sustainable Development Goal (SDG) target of reducing premature NCD mortality by one-third by 2030. This review examines the reasons for this situation to propose a way forward.

Cardiovascular Disease 59

Cardiovascular Disease Risk Factors Outcomes 59

Medical Xpress - Cardiology

FEBRUARY 14, 2025

Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg muscles may help detect cardiovascular disease earlier than standardized tests, opening the door to earlier treatment and better outcomes.

Heart Failure 101

Heart Failure Cardiovascular Disease Research Outcomes 101

European Journal of Heart Failure

OCTOBER 9, 2024

Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.

Diabetes 75

Diabetes Outcomes Heart Failure Obesity 75

Circulation

NOVEMBER 11, 2024

Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.

Risk Factors 40

Risk Factors Cardiovascular Disease Coronary Artery Bypass Graft Outcomes 40

Circulation

FEBRUARY 12, 2024

BACKGROUND:Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. METHODS:A total of 5047 participants with a mean±SD age of 57.2±10.0

Diabetes 80

Diabetes Outcomes Myocardial Infarction Heart Failure 80

Frontiers in Cardiovascular Medicine

JUNE 30, 2024

Cardiovascular disease (CVD) represents the leading cause of mortality and disability all over the world. Identifying new targeted therapeutic approaches has become a priority of biomedical research to improve patient outcomes and quality of life.

Cardiovascular Disease 52

Cardiovascular Disease Quality of Life Myocardial Infarction Aneurysm 52

The New England Journal of Medicine

AUGUST 30, 2024

Measurement of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a) predicted the 30-year cardiovascular disease risk among women enrolled in the Women’s Health Study.

Cholesterol 76

Cholesterol Cardiovascular Disease Outcomes 76

American College of Cardiology

MARCH 15, 2024

A high social vulnerability index (SVI) score was associated with worse cardiovascular disease outcomes, including premature cardiovascular death, according to results from a scoping review published March 6 in JACC: Advances.

Outcomes 63

Outcomes Cardiovascular Disease Article 63

Cardiovascular Diabetology

JULY 15, 2024

The atherogenic index of plasma (AIP) is a critical metric for predicting cardiovascular outcomes. However, its associations with cardiovascular disease mortality (CVM) and all-cause mortality (ACM) remain unc.

Cardiovascular Disease 52

Cardiovascular Disease Outcomes Research 52

Journal of the American Heart Association

FEBRUARY 28, 2024

We assessed the association of cannabis use (number of days of cannabis use in the past 30 days) with self‐reported cardiovascular outcomes (coronary heart disease, myocardial infarction, stroke, and a composite measure of all 3) in multivariable regression models, adjusting for tobacco use and other characteristics in adults 18 to 74 years old.

Myocardial Infarction 76

Myocardial Infarction Outcomes Heart Disease Stroke 76

JAMA Cardiology

JANUARY 16, 2024

This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease.

Cholesterol 105

Cholesterol Cardiovascular Disease Outcomes 105